Compare Bristol-Myers Squibb Co (BMY) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Bristol-Myers Squibb Co trades at $58.36 (market cap $116.30B), while Direxion Daily Semiconductor Bear 3X Shares trades at $45.9. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| BMY | SOXS | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $1.61K |
52-Week Low | $42.60 | $32.50 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $46.65, up 14.34% on the day amid semiconductor sector volatility. Technical indicators show a neutral overall signal with bearish moving averages. The ETF is scheduled for a 1:10 stock split on July 15, 2026, and declared a $0.04 dividend for H1-2026. Recent news highlights the ETF's role in betting against the AI-driven semiconductor rally, with SOXS down significantly over six months as chip stocks surge.
The outlook for SOXS remains highly speculative, offering leveraged inverse exposure to semiconductors. Key opportunities include hedging against a potential semiconductor downturn, but risks are extreme due to the ETF's bearish structure in a strong bull market. Volatility decay and the sector's momentum pose substantial threats to long-term holders, making it suitable only for tactical, short-term trading.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
